Cardiovascular Diseases
Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases
Pfizer, Flagship Pioneering, Quotient Therapeutics, cardiovascular diseases, renal diseases, somatic genomics, drug development, partnership
NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations
NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease
Arrowhead Pharmaceuticals Shifts Focus to Plozasiran, Deprioritizes Zodasiran in Cardiometabolic Drug Development
Arrowhead Pharmaceuticals, cardiometabolic drug, plozasiran, zodasiran, RNAi therapies, cardiovascular disease, triglycerides, LDL cholesterol
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development
Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.
AstraZeneca’s Oral PCSK9 Inhibitor AZD0780 Demonstrates Significant LDL-C Reduction in Phase 1 Trial
PCSK9 inhibitor, AZD0780, AstraZeneca, cholesterol reduction, phase 1 trial, statin therapy, hypercholesterolemia, cardiovascular disease
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.
Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS
Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.
Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos
Cytokinetics, Aficamten, Camzyos, clinical data, cardiovascular disease, myotonic dystrophy, heart failure, commercial strategy, market competition.
Differences and potential advantages of aficamten compared to BMS’s Camzyos
The recent analysis from Cytokinetics has highlighted several key differences and potential advantages of aficamten compared to Bristol Myers Squibb’s Camzyos, both of which are cardiac myosin inhibitors used in the treatment of obstructive hypertrophic cardiomyopathy (HCM). Key Differences Pharmacodynamic Profile: Aficamten, being a next-generation myosin inhibitor, has a different pharmacodynamic profile compared to mavacamten […]